Pembrolizumab

Myelodysplastic Syndromes

City of Hope Medical Centermonoclonal_antibodyPhase 1Active

CCC

49/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 65/ 100

Competitive context

137 Active assets in the Myelodysplastic Syndromes cohort.

Asset / Sponsor	Phase	Rating
Daunorubicin OHSU Knight Cancer Institute	Phase 3	BB
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University	Phase 4	BB
FILGRASTIM City of Hope Medical Center	Phase 4	BB
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Romidepsin Sawa Ito, MD	Phase 4	BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant

BBB

Indicative ·

72 / 100

estrogen-receptor negative breast cancerDormant

BB

Indicative ·

71 / 100

progesterone-receptor negative breast cancerDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.